Tuesday, May 11, 2021

1 PM EST

Sign-Up HERE

Pharmaceutical, medical device and life science companies continue to face escalating anti-corruption risks in the global marketplace.  Companies in these industries face a complex global maze of foreign government laws and regulations that create significant risks for global companies in these sectors.

The U.S. Department of Justice, the Securities and Exchange Commission, and foreign law enforcement partners, continue to target global companies in the drug, device and life science industries for anti-corruption activities.  Last year, despite the COVID-19 pandemic, the Justice Department and the SEC brought several significant enforcement actions against Novartis & Alcon, Herbalife, Alexion Pharmaceuticals, and Cardinal Health.

Blue Umbrella, a leading global technology company that delivers a suite of third-party risk management and compliance solutions, and Michael Volkov, Principal at The Volkov Law Group, are pleased to announce a risk and compliance focused webinar, Anti-Corruption Risks and Compliance Trends in the Pharmaceutical, Medical Device and Life Sciences Industries.  Joining Mike Volkov on the webinar will be Brad Gates, SVP Global Client Development, from Blue Umbrella.  Mike and Brad will address several important issues, including:

• U.S. Department of Justice and SEC enforcement focus on global companies involved in drug, medical device and life science industries.
• Understanding third-party anti-corruption risks in foreign health care markets arising from interactions with health care officials, regulators, physicians and other medical staff.
• How does a pharmaceutical company’s 10-year old third-party compliance program compare with a current high-growth technology company’s program facing equivalent risk exposure?
• Solving complex programmatic issues with best practices and technological solutions.